{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:59:23Z","timestamp":1791665963163,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejca.2023.113424","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T07:38:23Z","timestamp":1699601903000},"page":"113424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1987-8617","authenticated-orcid":false,"given":"Pien","family":"Debets","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen M.A.","family":"Dreijerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4943-8882","authenticated-orcid":false,"given":"Anton","family":"Engelsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2594-1486","authenticated-orcid":false,"given":"Max","family":"Dahele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm R.","family":"Haak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca V.","family":"Steenaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-6426","authenticated-orcid":false,"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Corssmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Willemien","family":"Menke\u2013van der Houven van Oordt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2023.113424_bib1","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993","volume":"49","author":"Kerkhofs","year":"2013","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2023.113424_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101500","article-title":"Health-related quality of life in adrenocortical carcinoma","volume":"11","author":"Steenaard","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ejca.2023.113424_bib3","first-page":"216","article-title":"Comparison between functional and non-functional adrenocortical carcinoma","volume":"167","author":"Sada","year":"2020","journal-title":"Surg (U S)"},{"issue":"11","key":"10.1016\/j.ejca.2023.113424_bib4","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO\u2013EURACAN clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113424_bib5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1245\/s10434-014-3944-7","article-title":"Surgical resection of synchronously metastatic adrenocortical cancer","volume":"22","author":"Dy","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2023.113424_bib6","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113424_bib7","first-page":"19","article-title":"European journal of endocrinology european society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors","volume":"10","author":"Fassnacht","year":"2018","journal-title":"Guillaume Assie"},{"issue":"3","key":"10.1016\/j.ejca.2023.113424_bib8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2023.113424_bib9","doi-asserted-by":"crossref","unstructured":"Baudin E., Jimenez C., Fassnacht M., et al. EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study. https:\/\/doi.org\/101200\/JCO20224016_suppl4596. 2022;40(16_suppl):4596\u20134596. doi:10.1200\/JCO.2022.40.16_SUPPL.4596.","DOI":"10.1200\/JCO.2022.40.16_suppl.4596"},{"issue":"2","key":"10.1016\/j.ejca.2023.113424_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2559.2007.02747.x","article-title":"The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas","volume":"51","author":"van't Sant","year":"2007","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.ejca.2023.113424_bib11","doi-asserted-by":"crossref","first-page":"R325","DOI":"10.1530\/ERC-15-0318","article-title":"Developing treatment for adrenocortical carcinoma","volume":"22","author":"Kerkhofs","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2023.113424_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1530\/EJE-21-0510","article-title":"S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study","volume":"186","author":"Elhassan","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.ejca.2023.113424_bib13","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s10147-021-02021-8","article-title":"Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience","volume":"26","author":"Uchihara","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.113424_bib14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1530\/EJE-13-0519","article-title":"Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center","volume":"169","author":"Ayala-Ramirez","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ejca.2023.113424_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2023.113424_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1507\/endocrj.K07-079","article-title":"Immunohistochemistry of a proliferation marker Ki67\/MIB1 in adrenocortical carcinomas: Ki67\/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas","volume":"55","author":"Ryo","year":"2008","journal-title":"Endocr J"},{"issue":"9","key":"10.1016\/j.ejca.2023.113424_bib17","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1634\/theoncologist.2016-0459","article-title":"Complete responses to mitotane in metastatic adrenocortical carcinoma-a new look at an old drug","volume":"22","author":"Reidy-Lagunes","year":"2017","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ejca.2023.113424_bib18","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ejca.2023.113424_bib19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/jso.23015","article-title":"Operative management for recurrent and metastatic adrenocortical carcinoma","volume":"105","author":"Datrice","year":"2012","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2023.113424_bib20","doi-asserted-by":"crossref","unstructured":"Ettaieb M.H.T., Duker J.C., Feelders R.A., et al. Synchronous vs. Metachronous Metastases in Adrenocortical Carcinoma: an Analysis of the Dutch Adrenal Network On behalf of the Dutch Adrenal Network. doi:10.1007\/s12672\u2013016-0270\u20135.","DOI":"10.1007\/s12672-016-0270-5"},{"issue":"5","key":"10.1016\/j.ejca.2023.113424_bib21","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00268-021-05957-0","article-title":"Adrenal surgery for synchronously metastatic adrenocortical carcinoma: a population-based analysis","volume":"45","author":"Wu","year":"2021","journal-title":"World J Surg"},{"issue":"16","key":"10.1016\/j.ejca.2023.113424_bib22","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.3390\/cancers14163904","article-title":"The overall survival and progression-free survival in patients with advanced adrenocortical cancer is increased after the multidisciplinary team evaluation","volume":"14","author":"Tizianel","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2023.113424_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fendo.2021.613248","article-title":"Current status and future targeted therapy in adrenocortical cancer","volume":"12","author":"Alyateem","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.ejca.2023.113424_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100422","article-title":"Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma","volume":"7","author":"Lagan\u00e0","year":"2022","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.ejca.2023.113424_bib25","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14656566.2022.2106128","article-title":"Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?","volume":"23","author":"Cremaschi","year":"2022","journal-title":"Expert Opin Pharmacother"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2024.115123","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:51Z","timestamp":1760733711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923007268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":25,"alternative-id":["S0959804923007268"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113424","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113424"}}